GlaxoSmithKline: Key support at 1561p
Nicolas Suiffet July 6, 2020 4:00 PM
GlaxoSmithKline and Sanofi, the two pharmaceutical giants, are discussing a 500 million pounds deal to supply the U.K. government with their potential coronavirus vaccine.
GlaxoSmithKline and Sanofi, the two pharmaceutical giants, are discussing a 500 million pounds deal to supply the U.K. government with their potential coronavirus vaccine, reported Bloomberg citing people familiar with the matter. The UK is considering buying the vaccine if it shows convincing results in clinical trials scheduled to begin in September. Sanofi, whose Pasteur Vaccines Division enjoys a solid reputation, particularly in the area of influenza, is currently working on two other projects.
From a chartist point of view, the stock price remains within a consolidation channel in place since April 2020. The daily Relative Strength Index (RSI, 14) is navigating around its neutrality area at 50%. The configuration is mixed. Prices need to stand above 1561p to maintain the short term bullish bias. A push above 1749p would validate a new bullish signal and would open a path to see 1857p. Alternatively, a break below 1561p would call for a reversal down trend with 1490p and 1415p as targets.
Source: GAIN Capital, TradingView
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
StoneX Financial Pte. Ltd. is not under any obligation to update this report.
Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.